News

PharmExec11h
Bristol Myers Squibb’s Cobenfy Falls Short in Phase III Trial as Add On Therapy for Schizophrenia
In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...
PharmExec10h
Making Real-World Evidence Work for Medicare: What CMS’s Draft Guidance Gets Right and What Needs Work
CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare ...
PharmExec9h
Sebela’s Novel Potassium-Competitive Acid Blocker Demonstrates Promise in Gastroesophageal Reflux Disease
Results from the dual Phase III TRIUMpH trials demonstrated the statistical superiority of tegoprazan over lansoprazole in ...
PharmExec17h
How Tariffs Might Impact Drug Pricing and Access
What effect will the tariffs have on drug pricing and patient access? Arda Ural: Over the last 20 years, our industry has taken advantage of the global, integrated economy. The vast majority of global ...